Acute Myeloid Leukemia Therapeutics Market is Expected to Reach $ 2.6 bn by 2026
The Global Acute Myeloid Leukemia Therapeutics Market was valued at US$754.38 Million in the year 2018 and is estimated to reach US$2.6 billion by 2026, at a CAGR of 16.9%.
Acute Myeloid Leukemia (AML) is one of the most commonly occurring leukemias and accounts for approximately 80% of the leukemia related deaths worldwide. AML is a genetically heterogenous neoplastic disorder that can occur with or without the involvement of peripheral blood. The disorder increases the number of myeloid cells in the bone marrows resulting in the failure of bone marrow, anemia, thrombocytopenia and granulocytopenia. Primary AML in adults most occurs due to non-random chromosomal abnormalities. Molecular abnormalities and change in the genetic expression of NPM1, DNMT3A, FLT3, IDH1/2, TET2, RUNX1, CEBPA, ASLX1, MLL, TP53, cKIT affect prognosis in patients.
Recent research suggests that the AML specific genetic alterations accumulates with age. Besides, the prevalence increases with age wherein the median age is calculated as 65 years. The treatment must be started immediately after diagnosis or else could end fatal. The remission rate of AML is >65% and individuals younger than 65 have a survival rate of >25% and is expected to live for >3 years.
According to International Agency for Research on Cancer, the estimated number of leukemia cases in 2018 alone is >437,000. Of which, >125,000 cases age above 70. Further, the leukemia population is expected to cross >500000 by the year 2025. Also, AML is slightly more common in male than female population. According to the American Cancer Society the number of cases of AML is estimated to be more than 21000 and the associated mortality could be more than 10000.
Traditional AML treatment involves chemotherapy followed by intensification or consolidation treatment. Also, AML for elderly and therapeutic care for relapse of AML are unstandardized. However, in 2017, there were many FDA drug approval which had entirely changed the AML treatment landscape altogether. Emergence of novel therapeutics, personalized treatment based on the biomarkers will offer productive commercial opportunities. Increasing geriatric population in several geographic locations also increases the risks of AML occurrence in turn will aid the market growth. Several unmet needs such as biomarkers for identifying the genetic abnormality, awareness of the disorder, early diagnosis of the disorder, treatment for elderly and AML relapse patients are said to deter the market growth. However, the recent drug approvals have encouraged the companies to investment more in R&D for identifying novel biomarkers through highly sensitive tests and further tests like PCR can identify single point mutations which helps in effective treatment of the AML patients.
Chemotherapeutic agents such as sapacitabine, laromustine and guadecitabine have shown promising results in treating geriatric AML population during the early stage trials. Also, researchers are avidly focusing on preventing the chemo-resistance along with other combinations. Stem cell transplant studies are also underway for determining to autologous and allogenic transplant requirements. Therapies targeting gene level changes such as FLT3 inhibitors (midostaurin, gilteritinib), IDH inhibitors (enasidenib, ivosidenib), HDAC inhibitors (vorinostat, panobinostat), BCL2 inhibitors (venetoclax) and Plk inhibitors (alisertib) are also becoming a significant part of the treatment regiments. Besides, immunotherapies involving monoclonal antibodies such as Gemtuzumab ozogamicin, checkpoint inhibitors and CAR T-cell therapy are expected to be play a pivotal role in the treatment of AML with significant progress.
The 7MM countries namely the US, France, Germany, Italy, Spain, the UK and Japan held the major market share of more than 70% of the total AML therapeutics market in 2017. This is said to reduce to about 59% by 2023. Till 2017, North American market held a significant proportion of the AML therapeutics market attributing to factors such as increasing geriatric population and incidence of AML. Also, the advancements in R&D, healthcare infrastructure, awareness, development of targeted therapies and hefty investments in R&D. North American region is expected to hold the market share through the forecast period. Besides, Asia Pacific is anticipated to contribute to the AML therapeutics market as an increase in geriatric population is seen in the Japan, China in the next few years. Also, the rise in R&D investments, awareness of cancer, rise of govt. funding for improving healthcare infrastructure and an inclination to targeted therapies for increasing the lifespan are expected to contribute to the market growth.
More than 50+ have been listed in the report including Abbvie Inc., Pfizer, Ubivac, Astellas Pharma, Sellas Lifescience, Amgen, Immunogen, Otsuka Pharmaceuticals, Cellularity, Novartis, Teva Pharmaceuticals, Takeda Pharma, Roche Lifesciences, Merck, Johnson & Johnson, Gilead Lifesciences, Bristol Mayer Squibb, Celgnene who are investing heftily for developing novel therapies for AML treatment. Also, there are more than 300 trials for AML at present. Upon obtaining approval, the drugs are set to change the course of the market growth to a greater extent.
Request for Sample Pages @ https://www.optimainsights.org/sample-request/164-acute-myeloid-leukemia-therapeutics-market
Acute Myeloid Leukemia Therapeutics Market Based on Treatment Class (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)
- Hypomethylating Agents
- FLT3 Tyrosine Kinase Inhibitors
- Anti-CD33 Antibody Drug Conjugates
- IDH2 Inhibitors
- Other Targeted Therapies
- Innovative Early-Stage Approaches
- Pipeline Analysis
Acute Myeloid Leukemia Therapeutics Market Based on Geographic Region (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)
- North America
Acute Myeloid Leukemia Therapeutics Market Competitive Analysis (Company Overview, SWOT Matrix, Financial, Product Overview, and Market Strategies)
- Abbvie Inc
- Teva Pharmaceutica Industries Ltd
- Novartis AG
- Pfizer Inc
- Jazz Pharmaceuticals
- Astellas Pharma Inc
- A combination of Venetoclax with hypomethylating agent elucidated high efficacy in the treating adults with TP53 mutated AML.
- BioXcel’s BXCL701, a candidate for AML treatment has been granted orphan drug status by FDA
- CC-486, a cytidine nucleoside analogue showed promising results and improvement of overall survival of AML patients.
- Provides detailed Analysis of the Market Structure along with forecast of the various segments and sub-segments.
- Provides a Comparative Analysis of Key Marketed and Pipeline Products.
- Provides Key Information on Players involved.
- Provides a Complete Overview of Market Segments and the Regional Outlook.
- Provides In-depth Coverage of Key News, including Major Mergers, Acquisitions and Product Development updates such as clinical trial progression updates and regulatory updates.
The Report Provides Key Insights on
- History of the Acute Myeloid Leukemia Therapeutics Market, 2015 to 2017
- Forecast of the Acute Myeloid Leukemia Therapeutics Market Growth till the year 2026
- The key market drivers, restraints, challenges, future opportunities and the market dynamics driving the Acute Myeloid Leukemia Therapeutics Market
- Analysis of potential growth segments which will drive the market
- Landscape analysis of the major companies, and new market entrants and companies which possess disruptive technologies which can change the trend of the entire market
- Key market approaches adopted by the organizations and in-depth intelligence of potential strategies which could alter the market dynamics
Key market approaches adopted by the organizations and in-depth intelligence of potential strategies which could alter the market dynamics
Download Complete TOC of the Report @ https://www.optimainsights.org/request-toc/164-acute-myeloid-leukemia-therapeutics-market
Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to make better business decisions towards attaining market leadership.
Mr Chucks G
+91 966 6620 365 (Asia) | +1 424 2554 365 (US)